Table 2. Indications and lesions sites of the included studies.
| Study | Indications | Locations | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| NFNET | PCN | Insulinomas | Adenocarcinoma | Metastasis | Head | Uncinate process | Body | Tail | ||
| Barthet 2019 | 14 | 17 | 0 | 0 | 0 | 13 | 0 | 10 | 8 | |
| Choi 2018 | 7 | 2 | 1 | 0 | 0 | 4 | 0 | 5 | 1 | |
| Crino 2018 | 0 | 0 | 0 | 7 | 1 | 3 | 2 | 3 | 0 | |
| Oleinikov 2019 | 18 | 0 | 9 | 0 | 0 | 10 | 5 | 8 | 2 | |
| Pai 2015 | 2 | 6 | 0 | 0 | 0 | NR | NR | NR | NR | |
| Scopelliti 2018 | 0 | 0 | 0 | 10 | 0 | 4 | 0 | 6 | 0 | |
| Song 2016 | 0 | 0 | 0 | 6 | 0 | 4 | 0 | 2 | 0 | |
| Dancour 2019 | 0 | 0 | 8 | 0 | 0 | 2 | 3 | 2 | 1 | |
| Yang 2019 | NR | NR | NR | NR | NR | NR | NR | NR | NR | |
| De la Serna 2018 | 3 | 6 | 0 | 0 | 0 | 3 | 1 | 5 | 0 | |
| Total | 44/117 (37.6%) | 31/117 (26.5%) | 18/117 (15.4%) | 23/117 (19.7%) | 1/117 (0.8%) | 43/107 (40.2%) | 11/107 (10.3%) | 41/107 (38.3%) | 12/107 (11.2%) | |
NFNET, non-functional neuroendocrine tumor; PCN, pancreatic cystic neoplasm; NR, not reported.